Private Capital Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Private Capital Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,419	Closed	-$133K	–	110
2021 Q1	$133K	Sell	12,419 -12,420	-50%	-$154K	0.02%	97
2020 Q4	$365K	Buy	+24,839	New	+$358K	0.07%	71
2016 Q4	–	Sell	-146,633	Closed	-$2.17M	–	122
2016 Q3	$2.17M	Buy	+146,633	New	+$1.69M	0.77%	41
2016 Q2	–	Sell	-25,000	Closed	-$231K	–	114
2016 Q1	$231K	Sell	25,000 -451,069	-95%	-$3.8M	0.1%	101
2015 Q4	$6M	Sell	476,069 -2,500	-0.5%	-$34.8K	2.59%	8
2015 Q3	$6.17M	Sell	478,569 -25,993	-5%	-$478K	2.58%	5
2015 Q2	$11M	Buy	504,562 +420,742	+502%	+$9.59M	3.59%	1
2015 Q1	$1.7M	Buy	+83,820	New	+$1.24M	0.62%	52

Other funds holding TRIL

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Private Capital Advisors's TRIL Position: Q2 2021 in Review

Private Capital Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2021, closing a stake of 12,419 shares — an estimated $133K sold.

Private Capital Advisors first reported a position in TRIL in Q1 2015 and held it in 8 quarters. The position peaked at $11M in Q2 2015. 137 funds tracked by Wall St. Rank hold TRIL as of Q2 2021.

Private Capital Advisors reported no remaining Trillium Therapeutics Inc. position as of Q2 2021 after selling out during the quarter.
Private Capital Advisors sold 12,419 Trillium Therapeutics Inc. shares in Q2 2021, an estimated $133K.
Private Capital Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2015 and held it in 8 quarters.
Private Capital Advisors's Trillium Therapeutics Inc. position peaked at $11M in Q2 2015.
137 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2021.

Based on Private Capital Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.